Abstract:Abstract Background Endoscopic submucosal dissection (ESD) is an established technique for resecting early gastrointestinal neoplastic lesions. However, for Barrett’s neoplasia treatment, piecemeal EMR has been the standard approach, leaving the efficacy of ESD for Barrett’s neoplasia unclear. Aims To assess the outcomes of Barrett’s neoplasia treated with ESD at a tertiary center in Canada. Methods This is a single center, retrospective study. All patients aged over 18 who underwent ESD for Barrett’s neoplasia at St. Michael’s Hospital between December 2017 and August 2023 were included. Primary outcomes were En-bloc, R0, curative resection, and recurrence rates, while secondary outcomes focused on the adverse event rate. Results Of the 72 patients studied (mean age 67.7 years; 90% male), 31.9% (23/72) were SSBE and 68.1% (49/72) were LSBE. The mean±SD lesion size was 4.5±3.4 cm, with circumferential occupancy at 53.4±23.9 %. Paris classifications were as follows: 0-Is: 8 (11.1%), 0-IIa: 26 (36.1%), 0-IIb: 9 (12.5%), 0-IIc: 6 (8.3%), 0-IIa+IIc: 13 (18.6%), 0-IIa+Is: 10 (13.9%). The mean operation time stood at 144.4 (75.3) minutes. Adverse events comprised deep mural injury (4.1%) and delayed bleeding (2.8%). Pathology findings showed high-grade dysplasia in 6.9% and adenocarcinoma in 93.1%, further differentiated as: well-differentiated (55%), moderately differentiated (33%), and poorly differentiated (12%). The invasion depth was intramucosal in 76%, SM1 in 6%, and SM2-SM3 in 18%. Lympho-vascular invasion was present in 22%. En-bloc, R0, and curative resection rates were 96% (69/72), 82% (59/72), and 64% (46/72), respectively. Of the curative resection patients, 42 have completed follow-up EGD, with 11.9% (5/42) showing persistent dysplasia at first follow-up. These were treated by either EMR (4 cases) or ESD (1 case), leading to a 100% (42/42) complete remission of dysplasia (CRD) rate with median follow-up time of 127 (68-190) days. After achieving CRD, local recurrence was found in 2.4% (1/42) with a median follow-up time of 289 (136-524) days. This recurrence post-CRD was successfully treated with EMR, regaining CRD. Conclusions Our study showcases the Canadian experience of using ESD for Barrett’s neoplasia at a large single tertiary referral center. Given the challenging demarcation lines in Barrett’s neoplasia and the frequent presence of metachronous lesions, even with curative resection, 11.9% showed persistent lesions during the first follow-up. However, these lesions were treatable endoscopically, with 100% eventually achieving CRD. Although there was a 2.4% recurrence rate post-CRD, this too could be managed endoscopically. Overall, the mid-term outcomes of treating Barrett’s neoplasia with ESD are promising. Funding Agencies None

Sa1464 Searching for the Limits: the Role of Endoscopic Resection (ER) in Submucosal Carcinoma (SMC) with Barrett's Esophagus (BE)

Tu1209 Predictive Factors Associated with Curative Endoscopic Eradication after Endoscopic Resection of Submucosal Esophageal Cancers

Complete Endoscopic Mucosal Resection is Effective and Durable Treatment for Barrett's-associated Neoplasia.

Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management

A retrospective study of endoscopic resection for 368 patients with early esophageal squamous cell carcinoma or precancerous lesions

S1517: Complete Barrett's Eradication Endoscopic Mucosal Resection (CBE-EMR): Long-Term Results of Management of High Grade Dysplasia (HGD) and Intramucosal Carcinoma (IMC)

A208 ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FOR BARRETT’S NEOPLASIA: CLINICAL OUTCOMES AND MID-TERM FOLLOW-UP AT A CANADIAN TERTIARY REFERRAL CENTER

Current Trends in Endoscopic Diagnosis and Treatment of Early Esophageal Cancer

Early esophageal cancer or precancerous lesions treated by endoscopic resection: a single-center retrospective study of 368 cases

Diagnosis and treatment of superficial esophageal cancer

Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection for Barrett’s Associated Neoplasia: A Systematic Review and Meta-analysis of the Published Literature

Prospective Evaluation of the Clinical Utility of Endoscopic Submucosal Dissection (ESD) in Patients with Barrett’s Esophagus: a Western Center Experience

Tu1607 an Interim Report of an Eight-Year Experience of Complete Barrett's Eradication by Endoscopic Mucosal Resection (CBE-EMR) for High Grade Dysplasia (HGD) or Intramucosal Carcinoma (IMC)

Su1496 Esophageal Endoscopic Mucosal Resection: Efficacy and Safety at a Tertiary Care Center

Rates of Recurrent Intestinal Metaplasia and Dysplasia After Successful Endoscopic Therapy of Barrett's Neoplasia by EMR vs ESD and Ablation: A Large North American Multicenter Cohort

Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma

The Efficacy of Additional Surgical Resection after Endoscopic Resection in Pt1b Esophageal Squamous Cell Carcinoma: A Multi-Institutional Retrospective Study in China

Pathological Analysis and Therapeutic Evaluation of Early Colorectal Carcinoma Treated by Endoscopic Resection or Surgery

[Endoscopic mucosal resection for early esophageal cancer with esophageal varices]

Endoscopic Ultrasonography and Submucosal Resection in the Diagnosis and Treatment of Rectal Carcinoid Tumors

Endoscopic Submucosal Dissection for Esophageal Cancer: Current and Future